Milestone Payments and Royalties. In consideration of the license granted under this Agreement, LICENSEE shall pay to BYU, in the manner designated below until the Agreement shall be terminated, as follows:
Milestone Payments and Royalties. The following provisions relate to milestone and royalty payments to be made by NWBio hereunder:
Milestone Payments and Royalties. The Milestone Payments and Royalties stated in this Agreement apply separately to the Initial Product and each New Product. The Parties may negotiate in good faith different research and development funding for each New Product than that provided for in Section V for the Initial Product according to the procedure stated below.
Milestone Payments and Royalties. Prior to the commercialization of the Products, the Management Committee shall consider and if appropriate, determine reasonable royalties and milestone payments with respect to the commercialization of the Products by Newco that shall be payable by Newco to Elan and Photogen, and shared by Elan and Photogen [****] (whether common stock and/or preferred stock) in Newco. ---------------- ---------------- [****] REPRESENTS MATERIAL WHICH HAS BEEN REDACTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. At such time, the Management Committee will agree to an appropriate definition of "Net Sales" as such term is used in this Agreement.
Milestone Payments and Royalties. Contingent on the following events, and subject to Sections 4.6 and 4.7, the following payments and royalties shall be paid by GHI (within thirty (30) days of such event) to Incyte for each Product with respect to Designated Gene/Gene Derivatives under respective license(s) as applicable. Product Stage Milestone See (a) & (b) below Royalties on Net Sales See (c) & (d) below
Milestone Payments and Royalties. Prior to the commercialization of the Products, the Management Committee shall consider and if appropriate, determine reasonable royalties and milestone payments with respect to the commercialization of the Products by Newco that shall be payable by Newco to Elan and Photogen, and shared by Elan and Photogen [****] with Elan's and Photogen's [****] in Newco. At such time, the Management Committee will agree to an appropriate definition of "Net Sales" as such term is used in this Agreement.
Milestone Payments and Royalties. 8.1 One-time Milestone Payments. Heska shall make one-time milestone --------------------------- payments to 3DP as follows: [**] In the event that Heska or its Affiliates or sublicensees are conducting Development on a particular Development Compound, and such Development efforts cease for any reason (other than Regulatory Approval), and Heska or its Affiliates or sublicensees subsequently select a different Development Compound (the "Replacement Compound") and commence Development on such Replacement Compound to replace the Development Compound that was dropped from Development, then Heska shall **Certain portions of this Exhibit have been omitted based upon a request for confidential treatment that has been filed with the Commission. The omitted portions have been filed separately with the Commission. not be obligated to pay any of the milestone payments set forth in Section 8.1.2 through 8.1.5 for achievement of the milestone events set forth therein by the Replacement Compound if such payments were previously made by Heska as a result of achievement of such milestone events by such Development Compound that was dropped from Development.
Milestone Payments and Royalties. Sections 4.3, 4.4 and 4.5 of the Agreement will be amended with respect only to the Additional QBI Products as follows:
Milestone Payments and Royalties. 8.1 One-time Milestone Payments. Heska shall make one-time milestone --------------------------- payments to 3DP as follows:
8.1.1 [**] payment, upon the Effective Date, for 3DP's development of the 3DP Intellectual Property to be used over the Research Term, which payment shall be non-refundable.
8.1.2 [**] upon the selection by Heska pursuant to Section 4.1 of the [**] Development Compound by Heska for use in the Primary Field.
8.1.3 [**] upon the selection by Heska pursuant to Section 4.1 of the [**] Development Compound by Heska for use in the other animal species in the Primary Field.
8.1.4 [**] within 15 days after the date on which a Regulatory Agency has accepted the [**] complete application for Regulatory Approval of a Licensed Product for use in the Primary Field.
8.1.5 [**] within 15 days after the date on which a Regulatory Agency has accepted the [**] complete application for Regulatory Approval of a Licensed Product for use in the Primary Field in the other animal species.
8.1.6 [**] upon the [**] Commercial Sale in the United States of any Licensed Product for use in the Primary Field.
8.1.7 [**] upon the [**] Commercial Sale in Europe of a Licensed Product for use in the Primary Field.
8.1.8 [**] upon the [**] Commercial Sale in the United States of any Licensed Product for use in the Primary Field in the other animal species. In the event that Heska or its Affiliates or sublicensees are conducting Development on a particular Development Compound, and such Development efforts cease for any reason (other than Regulatory Approval), and Heska or its Affiliates or sublicensees subsequently select a different Development Compound (the "Replacement Compound") and commence Development on such Replacement Compound to replace the Development Compound that was dropped from Development, then Heska shall **Certain portions of this Exhibit have been omitted based upon a request for confidential treatment that has been filed with the Commission. The omitted portions have been filed separately with the Commission. not be obligated to pay any of the milestone payments set forth in Section 8.1.2 through 8.1.5 for achievement of the milestone events set forth therein by the Replacement Compound if such payments were previously made by Heska as a result of achievement of such milestone events by such Development Compound that was dropped from Development.
Milestone Payments and Royalties. Following exercise of the Related Product Opt-In Right, Shire shall pay to Amicus royalty payments under Section 7.3 with respect to such Related Product as a Licensed Product. In addition, Shire shall pay to Amicus an additional set of Milestone payments for such Related Product, in an amount equal to [***] of the amounts for the achievement of the same events as provided for the first Licensed Product Developed for the same Field under Section 7.2.1, provided, that such payments shall not be due until the first Regulatory Approval of the first Licensed Product for the same disease within the Field as that of such Related Product. For clarity, upon Regulatory Approval of the first Licensed Product in a particular Field, payments for Milestones (as provided in this Section) for a Related Product previously achieved shall be due to Amicus.
